Surrogate Endpoint Biomarkers for Cervical Cancer Chemoprevention Trials

Journal of Cellular Biochemistry - United States
doi 10.1002/jcb.240590915
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cervical Cancer Chemoprevention, Vaccines, and Surrogate Endpoint Biomarkers

Cancer
Cancer ResearchOncology
2003English

Five Criteria for Using a Surrogate Endpoint to Predict Treatment Effect Based on Data From Multiple Previous Trials

Statistics in Medicine
EpidemiologyStatisticsProbability
2018English

Chemoprevention for Breast Cancer

Annals of Surgical Oncology
OncologySurgery
2015English

Candidate Biomarkers for Cervical Cancer Treatment: Potential for Clinical Practice (Review)

Molecular and Clinical Oncology
Cancer ResearchOncology
2014English

Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer Upon Anatomic Location

Oncologist
Cancer ResearchMedicineOncology
2019English

PPAR Ligands for Cancer Chemoprevention

PPAR Research
Drug DiscoveryPharmacology
2008English

Pcn290 - Use of PCR as a Surrogate Primary Endpoint in Drug Pivotal Trials in Neoadjuvant Early Breast Cancer in Eu: A Perspective From Regulators and Payers

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Assessing Toxicity in Cancer Chemoprevention Trials: The Other Side of the Coin

Cancer Prevention Research
MedicineCancer ResearchOncology
2008English

Targeting NRF2 Signaling for Cancer Chemoprevention

Toxicology and Applied Pharmacology
ToxicologyPharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy